NextCell Pharma AB banner
N

NextCell Pharma AB
STO:NXTCL

Watchlist Manager
NextCell Pharma AB
STO:NXTCL
Watchlist
Price: 1.25 SEK 1.63% Market Closed
Market Cap: kr139.2m

Wall St Price Targets

NXTCL Price Targets Summary
NextCell Pharma AB

Wall Street analysts forecast NXTCL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NXTCL is 3.57 SEK with a low forecast of 3.54 SEK and a high forecast of 3.68 SEK.

Lowest Forecast
Price Target
3.54 SEK
183% Upside
Average Forecast
Price Target
3.57 SEK
186% Upside
Highest Forecast
Price Target
3.68 SEK
194% Upside
NextCell Pharma AB Competitors:
Price Targets
CDNA
CareDx Inc
15% Upside
USEG
US Energy Corp
181% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Revenue Forecast
is not available for NextCell Pharma AB

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Operating Income Forecast
is not available for NextCell Pharma AB

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for NextCell Pharma AB
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is NXTCL's stock price target?
Price Target
3.57 SEK

According to Wall Street analysts, the average 1-year price target for NXTCL is 3.57 SEK with a low forecast of 3.54 SEK and a high forecast of 3.68 SEK.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett